Anti-RAGE

Code: ab9714-i D2-231

Not available outside of the UK & Ireland.

Application

Anti-RAGE, Cat. No. AB9714-I, is a highly specific rabbit polyclonal antibody that targets Advanced glycosylation end product-specific receptor and has been teste...


read more

Your Price
£514.00 EACH
£616.80 inc. VAT

Not available outside of the UK & Ireland.

Application

Anti-RAGE, Cat. No. AB9714-I, is a highly specific rabbit polyclonal antibody that targets Advanced glycosylation end product-specific receptor and has been tested in Immunohistochemistry (Paraffin) and Western Blotting.

Research CategoryNeuroscience

Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected RAGE in human lung tissue.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Advanced glycosylation end product-specific receptor (UniProt: Q15109; also known as Receptor for advanced glycosylation end products, RAGE) is encoded by the AGER (also known as RAGE) gene (Gene ID: 177) in human. RAGE is a single-pass type I membrane protein that contains two Ig-like C2-type domains, one Ig-like V-type domain, a 21 amino acid transmembrane domain and a 41 amino acids cytoplasmic domain. RAGE mediates interactions of advanced glycosylation end products (AGE), which are non-enzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. RAGE acts as a mediator of both acute and chronic vascular inflammation in conditions, such as atherosclerosis and in complication of diabetes. Blockage of RAGE is reported to suppress development of atherosclerosis and vascular disorders. RAGE is expressed by endothelium, mononuclear phagocytes, neurons and smooth muscle cells. Higher expression of RAGE is observed during development, especially in the central nervous system, and its levels decline during maturity. Besides binding to advanced glycosylation end product (AGE), RAGE also binds amyloid beta peptide, S100family proteins, and leukocyte integrins. Excessive amounts of amyloid peptides (Ab) in brain leads to the hyperstimulation of RAGE. The RAGE-Ab interaction is thought to result in oxidative stress leading to neuronal degeneration.

Immunogen

KLH-cojugated linear peptide corresponding to 20 amino acids from the N-terminal region of human RAGE.

Linkage

Replaces: AB9714

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Affinity Purified

Quality

Evaluated by Western Blotting in mouse lung tissue lysate.

Western Blotting Analysis: 2 µg/mL of this antibody detected RAGE in 10 µg of mouse lung tissue lysate.


Specificity

This polyclonal antibody detects Receptor for Advanced Glycosylation End Products (RAGE). This antibody targets an epitope corresponding to 21 amino acids in the N-terminal region of human RAGE. Human, mouse, and rat RAGE display 95% homology in this epitope region.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Target description

~48 kDa observed; 42.80 kDa calculated. Uncharacterized bands may be observed in some lysate(s).

antibody formaffinity isolated antibody
antibody product typeprimary antibodies
biological sourcerabbit
clonepolyclonal
Gene Informationhuman ... AGER(177)
NCBI accession no.NP_001127
purified byaffinity chromatography
Quality Level100
shipped inambient
species reactivity (predicted by homology)human (based on 100% sequence homology)
species reactivityrat, mouse
technique(s)western blot: suitable, immunohistochemistry: suitable (paraffin)
UniProt accession no.Q15109
This product has met the following criteria: